2025

2024

2025

2024

For the Three Months Ended
July 31,

For the Nine Months Ended
July 31,

2025

2024

2025

2024

Net loss:

Cancer Vaccines

$

(1,298

)

$

(2,160

)

$

(5,195

)

$

(5,628

)

CAR-T Therapeutics

(973

)

(1,145

)

(3,074

)

(4,115

)

Other

(9

)

(10

)

(37

)

(42

)

Total

$

(2,280

)

$

(3,315

)

$

(8,306

)

$

(9,785

)

$

(2,280

)

$

(3,315

)

$

(8,306

)

$

(9,785

)

Total operating costs and expenses

$

2,436

$

3,592

$

8,825

$

10,668

Less non-cash stock-based compensation

(855

)

(1,179

)

(2,899

)

(3,699

)

Operating costs and expenses excluding non-cash stock-based compensation

$

1,581

$

2,413

$

5,926

$

6,969

Operating costs and expenses excluding non-cash stock-based compensation:

Cancer Vaccines

$

884

$

1,614

$

3,714

$

3,988

CAR-T Therapeutics

689

789

2,180

2,943

Other

8

10

32

38

Total

$

1,581

$

2,413

$

5,926

$

6,969

Operating costs and expenses excluding non-cash stock-based compensation

$

1,581

$

2,413

$

5,926

$

6,969